Healthy Volunteers Clinical Trial
Official title:
Urinary Bactericidal Activity of 4 Doses of Levofloxacin (250, 500, &750, and 1000 mg) Against Fluoroquinolone-Resistant E. Coli
Single-dose studies of a fluoroquinolone are indicative of their antimicrobial activity
since little accumulation occurs with multiple doses. Single-dose studies have been utilized
to determine drug concentrations and time kill activity in serum, urine, and respiratory
tissues.
The purpose of this study is to evaluate the Urine Bactericidal Activity (UBA) of
levofloxacin (250, 500, 750, and 1000 mg) against FQ-resistant, ESBL positive E. coli
isolates. In addition, a susceptibility breakpoint concentration in the urine can also be
established for each dose of levofloxacin. Furthermore, urine concentrations and serum
pharmacokinetic parameters of levofloxacin can be determined.
Subjects: -10 healthy (from medical history) adult male or female volunteers
- Normal body weight (within 20 %)
- Age range: 18-60
- Not taking any other restricted medications (ie. antibiotics)
Drug : all drugs are a single dose given after a 12 hour fast
- 1000 mg.levofloxacin
- 750 mg. levofloxacin
- 500 mg levofloxacin
- 250 mg levofloxacin
Levofloxacin Pharmacokinetic Study:
A serum sample will be obtained prior to and at 1.5 (peak), 4.0, 8.0, 12 (50% of interval)
and 24 (100% of interval) hours after each single dose of levofloxacin (6 time points).
Levels will be determined by an HPLC assay.
Urine Pharmacodynamic Study:
A urine sample will be obtained prior to and at 1.5 (peak), 4, 8, 12 (50% of interval), and
24 (100% of interval) hours after a single dose of each dose of levofloxacin.
A urine pH will be run on each sample.
All urine levels will be determined by a validated HPLC assay.
Study Isolates: E. coli (TRUST isolates):
Levofloxacin MICs:
- 0.125 (sensitive)
- 4.0 (intermediate)
- 8.0 (resistant)
- 16.0 (resistant)
- 32.0 (resistant)
- 64.0 (resistant)
This MIC range of E. coli isolates should be able to define a levofloxacin susceptibility
breakpoint for urinary pathogens at each dose studied.
Urine Cidal Activity: Urine samples will be tested against each of the study isolates. A
maximum urine cidal titer will be determined for each urine. The median titer at each time
period (10 subjects) will determine the urine cidal activity.
The duration of cidal activity for each isolate will be determined and plotted. A 12-h
duration will be considered the minimum time necessary for prolonged Urine Bactericidal
Activity (MIC breakpoints).
Safety: All patients will be monitored for side effects during the study.
;
Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
| Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
| Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
| Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
| Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
| Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
| Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
| Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
| Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
| Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
| Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
| Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
| Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
| Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
| Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
| Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
| Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |